Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations / Neuroendocrine Tumor Research Advances · Journal article
P a Herzen Journal of Oncology · August 10, 2026
Reinforces what was already believed, rather than introducing something new.
This retrospective cohort of 58 patients treated with atezolizumab plus carboplatin–etoposide for advanced SCLC in routine practice reports median OS of 11.2 months, median PFS of 7.2 months, ORR of 58.6%, and a safety profile consistent with the pivotal IMpower133 trial. The findings support the reproducibility of the combination regimen in a less-selective, real-world population, though the single-center, retrospective design limits generalizability.
Retrospective single-center cohort study. 58 consecutive patients with advanced SCLC receiving first-line atezolizumab plus carboplatin–etoposide at Irkutsk Regional Oncology Dispensary; median age 63.3 years; 20.7% with ECOG 2; 13.8% with brain metastases.. Intervention: Atezolizumab in combination with carboplatin and etoposide (4–6 cycles induction followed by atezolizumab maintenance). n = 58. Irkutsk Regional Oncology Dispensary, Russia (single center).
Median overall survival: 11.2 months Median progression-free survival: 7.2 months Objective response rate: 58.6% (including 3.4% complete responses)
Adverse events or clinically significant laboratory abnormalities reported in 72.4% of patients; most common were anemia (43.1%) and leukopenia (22.4%)
Clinicians treating advanced SCLC may view this real-world data as reassuring confirmation that the IMpower133 regimen produces consistent outcomes outside controlled trials. However, the single-center, retrospective design and modest sample size should prompt caution before drawing practice conclusions; this study reinforces rather than changes existing evidence.
Retrospective single-center cohort study confirming efficacy and safety outcomes of atezolizumab plus chemotherapy in advanced SCLC, replicating key endpoints from the pivotal IMpower133 trial in a real-world population.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians treating advanced SCLC may view this real-world data as reassuring confirmation that the IMpower133 regimen produces consistent outcomes outside controlled trials. However, the single-center, retrospective design and modest sample size should prompt caution before drawing practice conclusions; this study reinforces rather than changes existing evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective. To evaluate the efficacy and safety of atezolizumab in combination with carboplatin and etoposide in the first-line treatment of advanced small cell lung cancer (SCLC) in real-life clinical practice. Material and methods. A retrospective single-center cohort study was conducted. The analysis included 58 consecutive patients with advanced SCLC who received atezolizumab plus carboplatin and etoposide in the first-line treatment from SEP/2020 to SEP/2025 at the Irkutsk Regional Oncology Dispensary. Database slice completed as of 04/MAR/2026. The primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints were objective response rate (ORR), disease control (DCR), completion of the induction phase of therapy, and safety profile. Survival analysis was performed using Kaplan-Meier method. Results. The median age of patients was 63.3 years; 20.7% of patients had ECOG 2, and brain metastases were detected in 13.8% of patients. The ORR was 58.6%, including 3.4% complete responses; DCR reached 82.8%. Median PFS was 7.2 months, median OS was 11.2 months. 75.9% of patients completed the induction stage of 4–6 cycles of therapy, after which they were switched to atezolizumab maintenance therapy. Adverse events or clinically significant laboratory abnormalities were reported in 72.4% of patients and the most common were hematologic complications, including anemia (43.1%) and leukopenia (22.4%). Immune-mediated complications were rare; a single case of myocarditis has been reported. Conclusion. Atezolizumab in combination with carboplatin and etoposide demonstrated clinically significant anti-tumor activity and acceptable tolerability in patients with advanced SCLC in a real-world setting. These results confirm the reproducibility of key effects of the IMpower133 pivotal study in a less selective population and support the use of this regimen as a first-line standard of care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.